Imatinib Sandoz (Imatinib Mesilate)

Imatinib Sandoz targets abnormal tyrosine‑kinase signaling in several hematologic and solid tumours.

• Chronic myeloid leukemia (CML): suppresses BCR‑ABL driven proliferation, achieving durable hematologic and cytogenetic responses.
• Gastrointestinal stromal tumor (GIST): inhibits c‑KIT and PDGFR, leading to tumour shrinkage and disease control.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): blocks BCR‑ABL activity, supporting remission induction and maintenance.

• Imatinib mesilate binds competitively to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This inhibition halts proliferative signaling pathways, induces apoptosis of malignant cells, and reduces tumor growth in diseases driven by these kinases.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the lower limbs.
• Muscle cramps: intermittent painful contractions.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools, sometimes watery.
• Rash: mild skin eruptions.

Serious or Rare Side Effects

• Neutropenia: marked reduction in white blood cells, increasing infection risk.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: reduced cardiac output, especially in patients with pre‑existing heart disease.
• Severe bleeding: gastrointestinal or intracranial hemorrhage.
• Interstitial lung disease: inflammatory lung infiltrates causing dyspnea.
• Tumor lysis syndrome: rapid tumour cell breakdown leading to metabolic disturbances.

Before initiating therapy, clinicians should evaluate baseline health status and monitor for specific risks.

• Monitor blood counts: perform regular CBC to detect neutropenia or anemia.
• Assess liver function: check transaminases and bilirubin periodically.
• Evaluate cardiac status: baseline ECG and echocardiogram for patients with cardiac history.
• Avoid strong CYP3A4 inhibitors: concomitant use may raise imatinib exposure.
• Use caution in pregnancy: limited data; weigh potential benefits against risks.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Imatinib may interact with drugs that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase plasma levels.
• Concurrent use with other tyrosine‑kinase inhibitors: may amplify toxicity.
• Warfarin: may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug concentrations.
• Proton pump inhibitors: may modestly affect absorption, requiring clinical observation.
• Diuretics: can exacerbate fluid retention; monitor electrolytes and weight.